Pfizer’s arthritis drug Xeljanz shows lifesaving benefits in hospitalized COVID-19 patients

Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty may be getting all the attention these days, but the pharma giant’s anti-inflammatory drug Xeljanz just chalked up a win in treating patients hospitalized with the disease.

Xeljanz reduced the risk of death or respiratory failure among hospitalized patients with COVID-19 pneumonia who didn’t require ventilation, according to data published in the New England Journal of Medicine.